Enhancement of dissolution rate of valdecoxib by solid dispersions technique with PVP K 30 & PEG 4000: Preparation and in vitro evaluation

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 63, Issue 1-2, 2009, Pages 69-75

  Shah, Jigar ^a   Vasanti, S ^b   Anroop, B ^c   Vyas, Hiral ^d  

^a NIRMA UNIVERSITY   (India)

^b PES COLLEGE OF PHARMACY   (India)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d Arihant School of Pharmacy   (India)

Author keywords

Dissolution; Polyethylene glycol; Polyvinylpyrrolidone; Solid dispersion; Stability; Valdecoxib

Indexed keywords

EID: 58549089172     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-008-9490-9     Document Type: Article

References (33)

1. DQM Craig 2002 The mechanisms of drug release from solid dispersions in water-soluble polymers Int. J. Pharm. 231 131 144 10.1016/S0378-5173(01)00891-2
2. C Leuner J Dressman 2000 Improving drug solubility for oral delivery using solid dispersions Eur. J. Pharm. Biopharm. 50 47 60 10.1016/S0939-6411(00) 00076-X
3. Swarbrick, J., Boylan, J.C.: Encyclopedia of Pharmaceutical Technology. Marcel Dekker, New York (2001)
4. RN Saha C Sajeev PK Priya C Sreekhar G Shashikanth 2002 Solubility enhancement of nimesulide and ibuprofen by solid dispersion technique Indian J. Pharm. Sci. 64 529 534
5. DM Patel RR Shah PD Jogani 2003 Studies to enhance dissolution of piroxicam Indian J. Pharm. Sci. 65 264 267
6. S Rawat LF Asgar SK Jain 2003 Formulation development studies of rofecoxib Indian J. Pharm. Sci. 65 367 370
7. R Kaur DJW Grant T Eves 1980 Comparison of PEG and polyoxyethylene stearate as excipients for solid dispersion systems of griseofulvin & tolbutamide I, II: phase equilibria J. Pharm. Sci. 69 1317 1326 10.1002/jps.2600691121
8. AP Simonelli SC Mehta WL Higuchi 1969 Dissolution rates of high energy PVP-sulfathiazole coprecipitates J. Pharm. Sci. 58 538 549 10.1002/jps. 2600580503
9. Wade, A., Paul, J.W.: Handbook of Pharmaceutical Excipients. Pharmaceutical Press, Washington (1994)
10. MC Tros De Ilarduya C Martin MM Goni MC Martinez-Oharriz 1998 Solubilization and interaction of sulindac with polyvinylpyrrolidone K30 in the solid state and in aqueous solution Drug Dev. Ind. Pharm. 24 295 300 10.3109/03639049809085623
11. E Broman C Khoo LS Taylor 2001 A comparison of alternative polymer excipients and processing methods for making solid dispersions of a poorly water soluble drug Int. J. Pharm. 222 139 151 10.1016/S0378-5173(01)00709-8
12. TR Bates WL Higuchi 1969 Dissolution characteristics of reserpine-PVP coprecipitates J. Pharm. Sci. 21 710 712
13. B Albertini C Cavallari N Passerini GML Onzalez-Rodriguez L Rodriguez 2003 Evaluation of β-lactose, PVP K12 and PVP K90 as excipient to prepare piroxicam granules using two wet granulation techniques Eur. J. Pharm. Biopharm. 56 479 487 10.1016/S0939-6411(03)00114-0
14. RN Pan JH Chen RR Chen 2000 Enhancement of dissolution and bioavailability of piroxicam in solid dispersion systems Drug Dev. Ind. Pharm. 26 989 994 10.1081/DDC-100101327
15. V Tantishaiyakul N Kaewnopparat S Ingkatawornwong 1999 Properties of solid dispersion of piroxicam in PVP Int. J. Pharm. 181 143 151 10.1016/S0378-5173(99)00070-8
16. Physicians Desk Reference, Medical Economics Company Inc., New Jersey, 2577 (2003)
17. GS Jadhav PR Vavia 2004 Development and pharmacodynamic evaluation of tablet containing inclusion complex of valdecoxib with β-cyclodextrin Indian J. Pharm. Sci. 60 525 526
18. JJ Talley 2000 A potent and selective inhibitor of COX-2 J. Med. Chem. 43 775 777 10.1021/jm990577v
19. Product Monograph, Bextra™, Pharmacia Canada Inc., Mississauga Ontario, Pfizer Canada Inc., Kirkland Quebec. http://www.pfizer.ca. Accessed on 19 November 2006
20. AA Ambike KR Mahadik A Paradkar 2004 Stability study of amorphous valdecoxib Int. J. Pharm. 282 151 162 10.1016/j.ijpharm.2004.06.009
21. C Liu KGH Desai C Liu 2005 Solubility of valdecoxib in the presence of poly (ethylene glycol) 4000, poly (ethylene glycol) 6000, poly (ethylene glycol) 8000, and poly (ethylene glycol) 10 000 at (298.15, 303.15, and 308.15) K J. Chem. Eng. Data 50 278 282 10.1021/je049667h
22. C Liu C Liu KGH Desai 2005 Enhancement of dissolution rate of valdecoxib using solid dispersions with polyethylene glycol 4000 Drug Dev. Ind. Pharm. 31 1 10
23. S Gurusamy V Kumar DN Mishra 2006 Preparation, characterization and in vitro dissolution studies of solid systems of valdecoxib with chitosan Chem. Pharm. Bull. 54 1102 1106 10.1248/cpb.54.1102 (Tokyo)
24. A Modi P Tayade 2006 Enhancement of dissolution profile by solid dispersion (Kneading) technique AAPS PharmSciTech 7 3 68 10.1208/pt070368
25. T Higuchi JL Lach 1954 Investigation of some complexes formed in solution by caffeine: IV. Interactions between caffiene and sulfathiazole, sulfadiazine, p-aminobenzoic acid, benzocaine, phenobarbital, and barbital [J] J. Am. Pharm. Assoc. Sci. Ed. 43 349 354
26. KA Khan 1975 The concept of dissolution efficiency J. Pharm. Pharmacol. 27 48 49
27. NH Anderson M Bauer N Boussac Khan R Malek P Munden M Sardaro 1998 An evaluation of fit factors and dissolution efficiency for the comparison of in vitro dissolution profiles J. Pharm. Biomed. Anal. 17 811 822 10.1016/S0731-7085(98)00011-9
28. T Higuchi K Connors 1965 A phase solubility technique Adv. Anal. Chem. Instrum. 4 117 211
29. AP Mukne MS Nagarsenker 2004 Triamterene-β-cyclodextrin systems: preparation, characterization and in vivo evaluation AAPS PharmSci Tech 5 E19 10.1208/pt050119
30. Gareth, A.L., Didier, M., Roger, P.T.L.: Pharmaceutical Experimental Design. Marcel Dekker, New York (1999)
31. NR Rao KPR Chowdary 2001 Improvement of dissolution rate and bioavailability of piroxicam with pregelatinized starch Indian J. Pharm. Sci. 63 36 40
32. RD Dabholkar MR Redkar PV Devrajan PV Solusorb 2004 A novel technology for solubilization of poorly soluble drugs Indian J. Pharm. Sci. 60 517 518
33. S Rawat SK Jain 2004 Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes Eur. J. Pharm. Biopharm. 57 263 267 10.1016/j.ejpb.2003.10.020